XOMA Corporation
General ticker "XOMAO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $424.6M (TTM average)
XOMA Corporation does not follow the US Stock Market performance with the rate: -17.3%.
Estimated limits based on current volatility of 0.0%: low 25.00$, high 25.01$
Factors to consider:
- Earnings expected soon, date: nan
- Company pays dividends (quarterly): last record date 2026-07-02, amount 0.52$ (Y8.32%)
- Total employees count: 160 as of 1997
- US accounted for 42.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Acquisition/divestiture risks, Product development failure, Integration challenges, Cybersecurity threats
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.44$, 31.29$]
- 2026-12-31 to 2027-12-31 estimated range: [19.47$, 32.75$]
Financial Metrics affecting the XOMAO estimates:
- Positive: with PPE of 14.6 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 21.83 > 18.65
- Positive: 19.10 < Shareholder equity ratio, % of 30.78 <= 42.34
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.42 > 6.08
- Negative: Industry earnings per price (median), % of -12.84 <= 0
- Negative: 0.75 < Interest expense per share per price, % of 2.84
- Negative: Inventory ratio change, % of 2.19 > 0.80
- Positive: Investing cash flow per share per price, % of 11.09 > -0.65
- Negative: negative Industry operating cash flow (median)
- Positive: 0.30 < Operating cash flow per share per price, % of 0.63
Short-term XOMAO quotes
Long-term XOMAO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4.76MM | $28.49MM | $52.15MM |
| Operating Expenses | $46.61MM | $68.46MM | $40.77MM |
| Operating Income | $-41.85MM | $-39.98MM | $11.38MM |
| Non-Operating Income | $1.02MM | $20.50MM | $20.43MM |
| Interest Expense | $0.57MM | $13.84MM | $13.03MM |
| R&D Expense | $0.14MM | $2.88MM | $1.71MM |
| Income(Loss) | $-40.83MM | $-19.48MM | $31.82MM |
| Taxes | $0.00MM | $-5.66MM | $0.10MM |
| Net Income(Loss)* | $-40.83MM | $-13.82MM | $31.71MM |
| Stockholders Equity | $88.72MM | $81.92MM | $83.94MM |
| Assets | $234.30MM | $221.28MM | $272.70MM |
| Operating Cash Flow | $-18.16MM | $-13.75MM | $2.87MM |
| Capital expenditure | $0.02MM | $0.02MM | $0.00MM |
| Investing Cash Flow | $-0.71MM | $-28.26MM | $50.89MM |
| Financing Cash Flow | $120.59MM | $-11.13MM | $-26.46MM |
| Earnings Per Share** | $-3.56 | $-1.18 | $1.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.